 Biocept Inc NASDAQ:BIOC revealed that it has expanded the commercial availability of CNSide, which is based on its proprietary quantitative tumor cell capture and detection method, paired with assays to identify actionable molecular treatment targets, to patients with metastatic melanoma. Previously validated for lung, breast, and all other carcinomas, the San Diego, California-based companys CNSide is a proprietary cerebrospinal fluid CSF assay designed to better detect metastatic cancers involving the central nervous system CNS. 